ChemPartner PharmaTech Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 1.67%

ChemPartner PharmaTech Co Ltd (300149) has an Asset Resilience Ratio of 1.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥33.99 Million

≈ $4.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.04 Billion

≈ $298.52 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how ChemPartner PharmaTech Co Ltd's Asset Resilience Ratio has changed over time. Check ChemPartner PharmaTech Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down ChemPartner PharmaTech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ChemPartner PharmaTech Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥33.99 Million	1.67%
Total Liquid Assets	CN¥33.99 Million	1.67%

Asset Resilience Insights

Limited Liquidity: ChemPartner PharmaTech Co Ltd maintains only 1.67% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ChemPartner PharmaTech Co Ltd Industry Peers by Asset Resilience Ratio

Compare ChemPartner PharmaTech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Genfit S.A. PA:GNFT	Biotechnology	64.01%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	22.98%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for ChemPartner PharmaTech Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for ChemPartner PharmaTech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.24%	CN¥45.57 Million ≈ $6.67 Million	CN¥2.03 Billion ≈ $297.48 Million	+2.19pp
2024-12-31	0.05%	CN¥1.05 Million ≈ $153.04K	CN¥2.00 Billion ≈ $292.05 Million	-0.04pp
2023-12-31	0.09%	CN¥2.21 Million ≈ $322.75K	CN¥2.43 Billion ≈ $356.22 Million	-0.36pp
2021-12-31	0.45%	CN¥18.98 Million ≈ $2.78 Million	CN¥4.22 Billion ≈ $617.17 Million	-0.04pp
2020-12-31	0.49%	CN¥20.08 Million ≈ $2.94 Million	CN¥4.12 Billion ≈ $603.12 Million	-1.22pp
2019-12-31	1.71%	CN¥64.40 Million ≈ $9.42 Million	CN¥3.77 Billion ≈ $551.34 Million	-10.21pp
2017-12-31	11.92%	CN¥124.34 Million ≈ $18.19 Million	CN¥1.04 Billion ≈ $152.65 Million	-27.54pp
2016-12-31	39.46%	CN¥313.00 Million ≈ $45.80 Million	CN¥793.16 Million ≈ $116.06 Million	-3.92pp
2015-12-31	43.39%	CN¥328.00 Million ≈ $48.00 Million	CN¥756.00 Million ≈ $110.63 Million	+38.26pp
2014-12-31	5.13%	CN¥38.00 Million ≈ $5.56 Million	CN¥741.13 Million ≈ $108.45 Million	--

pp = percentage points

About ChemPartner PharmaTech Co Ltd

SHE:300149 China Biotechnology

Market Cap

$709.73 Million

CN¥4.85 Billion CNY

Market Cap Rank

#10277 Global

#2628 in China

Share Price

CN¥9.74

Change (1 day)

-4.32%

52-Week Range

CN¥7.55 - CN¥14.24

All Time High

CN¥24.07